Search 

Gynotech is a developer of SMAT solutions for uro-gynecology conditions such as vaginal prolapse  and urinary incontinence.

Gynotech has developed the first smart, dynamic pessary that automatically adjust its size in response to the changing intr-abdominal pressures and thus provides a much better prevention of prolapse and urinary leakages.

The device is still at a development stage.

Hylomorph is a newly formed medical device company based in Switzerland with a breakthrough technology to improve the biocompatibility of medical implants. Upon implantation, devices such as cardiac implantable electronic devices or breast implants are perceived as a foreign body resulting in the formation of fibrotic (scar) tissue around the implant over time. This can lead to severe complications both for patient and surgeon during revision surgery resulting in additional costs of care.

Hylomorph has developed a novel material from biocellulose which has a unique macro and micro morphology disrupting both protein and fibroblast adhesion, blocking the process of fibrotic capsule formation.  This material can be formed into a variety of shapes which can be placed around the implantable device, both acting as a physical barrier and an active anti-fibrotic membrane.

Hylomorph is applying this technology to the two largest implantable medical device markets: cardiac implantable electronic devices, and breast implants, aiming to reduce significantly the clinical and economic problems associated with fibrotic capsule formation. Clinical trials will commence in 2018 with CE mark and FDA 510k clearance planned for 2020.     

Series A planned for Q2 2018

ID-NEST is currently developping a new, disruptive way to rebuild vascular bifurcations. Targeted indications are Aortic Arch Aneurysms and Compressed Veins. Our technology focuses on a patented way to connect 2 self-expandable stents on site, in order to restore native vessel capacities. 

endograft, stent graft, deep vein thrombosis, post-thrombotic syndrom, compressed veins, aortic arch aneurysms, self-expanding stents

Experienced and complementary team.

Scientific Committee comprises Pr Nabil Chakfé (Strasbourg), Dr Philippe Nicolini (Lyon), Pr Gerard O'Sullivan (Galway), Pr Stephen Black (London), Pr Armando Mansilha (Porto), Dr Olivier Hartung (Marseille).

Operational Team comprises:

. C. Tézenas du Montcel, CEO, MBA, 20+ years of experience at Management level in the Vascular Devices industry,

. William Wiecek, COO, 25+ years in the Medical Devices Industry. QA/RA specialist.

We're looking at a 10 millions € need, with a first slice of 2 millions € now to fund the Technological Development, followed by a 8 millions € slice to fund the clinicals

The “external fixators” (FixEx) used to date have already provided the outstanding service of stabilizing bone fractures in case of serious injuries, open bone fractures and severe joint fractures for decades. With all “external fixator” systems, four to six bone pins are screwed through the skin and into the bone. A fixation device (the actual “external fixator”) is then attached to these bone pins externally. Very often so-called “trauma fixators” are then removed after a few days or weeks once the patient’s overall condition has stabilized. The bone fracture is then definitively stabilized using a plate and screws or intramedullary nails. However, mounting the “external fixator” systems that are currently on the market is enormously time-consuming and error-prone and can only be reliably implemented by experienced orthopedic surgeons.  

The technical invention “snake FX” by the Erlangen-based startup nice!innovations GmbH has profoundly revolutionized the “external fixator” and its use in orthopedics and accident surgery. It is a conceptually completely new and an already well-developed product that enables an enormously clever, incomparably fast, incredibly simple method for stabilization of bone fractures by means of an unprecedented “snake principle”. Its “one-step rapid fixation technology” allows “snakeFX” to both fix the external fixator to the bone pins and stabilize the “FixEx” in a single step! Using traditional external fixator systems, both tasks involved time-consuming and error-prone mounting operations. Patents for “snake FX” have already been awarded for Europe, US, Brazil and Japan!

Precisely these unique selling points are leveraged when it comes to distribution: An initial estimate from Switzerland illustrates the high cost-saving potential combined with a dramatic increase in the quality of care for the patient. In Switzerland, one minute in the operating room costs 80 CHF. It takes trained orthopedic and trauma surgeons anywhere from 60 to 120 minutes for mounting and to make fine adjustments. The “snakeFX” aims to reduce this time to about 15 minutes.    

nice!innovations GmbH is currently developing the “snakeFX” into an approved product that is ready for series production. A crowd-financing campaign on www.aescuvest.de had collected more than 260,000 euros for this purpose as of February 2016 (in the form of subordinated loans). Following successful prototyping (expected in Q3/2017), snakeFX can obtain CE approval and be prepared for series production (target Q3/2018) within 9 to 12 months. The service provider for carrying out CE certification (Risk Class 1s; assessment by the “Notified Bodies” is available) has already been commissioned; a usability study with trauma surgeons, prototype-testing in a certified testing laboratory and a clinical trial are currently being conceptualized and implemented. An investor or strategic partner is being sought for the subsequent international commercialization of “snakeFX”.

Launched in Jan-2016, Paragate Medical is an Israeli innovative startup, aiming to revolutionize the heart failure epidemic management by introducing the first implantable medical device that actively and continuously prevents fluid overload in congestive heart failure patients. The device absorbs systemic extracellular fluid and drains it to the urinary system in a safe and controlled manner.

With its encouraging pre-clinical results and strong IP coverage, the company is currently looking to complete series A to support European based operation towards FIM trials.

Medical Device, Cardiology, Heart Failure, Minimally invasive implantable, Early Stage

Paragate's IPU is a minimally invasive, fully implantable device that continuously and actively drains excess systemic extracellular fluid, maintaining fluid overloaded heart failure patients in normal volumes and reducing the need for repeated hospitalizations for acute treatments.

Portabiles HealthCare Technologies GmbH has been founded in Nürnberg, Germany, in Dec/2016 by an experienced Management and scientific Team: Ralph Steidl (CEO), Prof. Dr. med. Jochen Klucken (University Hospital Erlangen), Prof. Dr. Björn Eskofier (University Erlangen-Nürnberg). The team works closely together since more than seven years and holds extensive competences in the fields of movement disorders, healthcare platforms, wearable technology, machine learning, data mining, and general management.

gait analysis, wearables, Medical Device, sensors, algorithms, falls prevention,

We raised in total 645.000 € through shareholder capital, convertible loans, public funding.

For medical device development, approval in Europe and US, and for sales efforts,  another  1 M € are required.

Worsening of the human gait is an important symptom in many chronic diseases and reason for most of the falls of elderly. An objective analysis of a patient's gait during activities of daily living delivers valuable information about the progress of a disease, the efficacy of a therapy (or a new drug), and the patient’s individual risk of falling.
Mobile GaitLab consists of motion sensors integrated into the patient's shoes (prepared orthopedic shoes). They measure the gait dynamics and provide clinical grade gait parameters to the therapist (Medical Device class IIa). Doctors thereby will be able to adjust therapy solely based upon those data.
Mobile GaitLab supports clinical trials for proving the efficacy of new drugs, tele-healthcare concepts (e.g. medication adjustment in Parkinson's Disease), and at a later stage prevention of falls. 

RetinAI Medical is a Swiss company that supports eye care professionals and patients throughout the medical examination process using Artificial Intelligence (AI). Our vision is to foster the transition from reactive medicine to preventive medicine for high-impact diseases such as Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and Glaucoma. 

Our solutions rely on the latest advances in medical image analysis, ophthalmology and machine learning. We have a unique team of scientists working to fully realize the capabilities of AI, and to integrate this technology into the next generation of medical devices.

ophthalmology, machine learning, artificial intelligence, healthcare, diagnosis, support, information and technology

Scailyte AG is an innovative Swiss-based company developing artificial intelligence (AI) technology for clinical research and diagnostics. We are offering a unique solution for the discovery of novel biomarkers for ultra-sensitive and early diagnosis of complex diseases such as cancer.

artificial intelligence, diagnostics, single-cell, medtech, biomarker, big data

TechsoMed is an Israeli based medical device company, developing BioTrace™, a real-time, monitoring and control system for thermal ablation procedures. The technology is applicable to multiple fields such as Oncology (tumor ablation), Cardiac (arrhythmia) and Pain management. Our breakthrough technology (based on two granted patents) is the only one which can give physicians real time monitoring and control for ablation procedures, and it can do all that by interfacing with standard ultrasound devices. The control and security we can give physicians will make our system a must-have for major ablation treatments.